﻿<?xml version="1.0" encoding="UTF-8"?>
<ArticleSet>
  <Article>
    <Journal>
      <PublisherName>Society of Diabetic Nephropathy Prevention</PublisherName>
      <JournalTitle>Journal of Nephropathology</JournalTitle>
      <Issn>2251-8363</Issn>
      <Volume>14</Volume>
      <Issue>3</Issue>
      <PubDate PubStatus="ppublish">
        <Year>2025</Year>
        <Month>07</Month>
        <DAY>01</DAY>
      </PubDate>
    </Journal>
    <ArticleTitle>Citrate versus heparin lock in hemodialysis catheter’s complications; a randomized clinical trial</ArticleTitle>
    <FirstPage>e27589</FirstPage>
    <LastPage>e27589</LastPage>
    <ELocationID EIdType="doi">10.34172/jnp.2025.27589</ELocationID>
    <Language>EN</Language>
    <AuthorList>
      <Author>
        <FirstName>Mahsa</FirstName>
        <LastName>Kohansal Vajargah</LastName>
        <Identifier Source="ORCID">https://orcid.org/0009-0007-8263-9949</Identifier>
      </Author>
      <Author>
        <FirstName>Fereshteh</FirstName>
        <LastName>Saddadi</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0003-4671-2962</Identifier>
      </Author>
      <Author>
        <FirstName>Mohammad Hassan</FirstName>
        <LastName>Fallahkohan</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0002-3200-399X</Identifier>
      </Author>
      <Author>
        <FirstName>Shahrzad</FirstName>
        <LastName>Ossareh</LastName>
        <Identifier Source="ORCID">https://orcid.org/0000-0003-3020-9465</Identifier>
      </Author>
    </AuthorList>
    <PublicationType>Journal Article</PublicationType>
    <ArticleIdList>
      <ArticleId IdType="doi">10.34172/jnp.2025.27589</ArticleId>
    </ArticleIdList>
    <History>
      <PubDate PubStatus="received">
        <Year>2024</Year>
        <Month>10</Month>
        <Day>24</Day>
      </PubDate>
      <PubDate PubStatus="accepted">
        <Year>2025</Year>
        <Month>03</Month>
        <Day>12</Day>
      </PubDate>
    </History>
    <Abstract>Introduction: Permanent central venous catheters (CVCs) are utilized in patients undergoing chronic hemodialysis who lack alternative vascular access or are awaiting kidney transplantation or the development of a long-term vascular access. The primary complications associated with CVCs include catheter-related infections (CRIs) and catheter lumen thrombosis, collectively contributing to catheter dysfunction. Objectives: This study aimed to compare the efficacy of 4% sodium citrate and heparin lock solutions in maintaining hemodialysis catheters, focusing on catheter dysfunction and infection, coagulation parameters, and serum calcium levels. Patients and Methods: This randomized clinical trial included 58 patients undergoing chronic hemodialysis, who were randomly assigned into two parallel groups. The intervention group (Citra-Lock; n = 29) received a lock solution containing 4% sodium citrate, while the control group (Heparin-Lock; n = 29) was administered a heparin 5000 IU lock. Data regarding hemorrhagic or coagulation events (e.g., prolonged partial thromboplastin time [PTT]), infections, catheter-related obstructions, and bleeding at the catheter site were prospectively collected and analyzed in both groups. Data were analyzed using SPSS software version 27, with a P value &lt; 0.05 considered statistically significant. Results: The male-to-female ratio in the study population was 1.52. A significant difference was observed in PTT changes between Citra-Lock and heparin-lock groups (P&lt;0.001). However, no significant differences were found in platelet counts or international normalized ratio (INR) levels (186750±9580 versus 175586±10424 and 1.00 versus 1.00; P= 0.247, P=0.326 respectively). Besides, there were no statistically significant differences in catheter related complications (P=0.669). Conclusion: In patients with durable hemodialysis catheters, the administration of a 4% sodium citrate lock solution was associated with fewer changes in PTT compared to heparin locks, without increasing the risk of infections or other catheter-related complications. Trial registration: The trial was approved by the Iranian registry of clinical trial (identifier: IRCT20231018059761N1; https://irct.behdasht.gov.ir/trial/75555, ethical code; IR.IUMS.FMD. REC.1402.459).  </Abstract>
    <ObjectList>
      <Object Type="keyword">
        <Param Name="value">Hemodialysis</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Catheter-related infections</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Citra-Lock</Param>
      </Object>
      <Object Type="keyword">
        <Param Name="value">Heparin-Lock</Param>
      </Object>
    </ObjectList>
  </Article>
</ArticleSet>